Why J codes matter for new bladder cancer treatments

In this video, Jonathan Rubenstein, MD, a urologist with Chesapeake Urology in Towson, Maryland, discusses how reimbursement logistics—particularly the availability of J codes—shape adoption of new therapies for non–muscle invasive bladder cancer (NMIBC).

Although patient outcomes and treatment efficacy remain the primary drivers of clinical decision-making, financial realities inevitably influence whether practices can offer new medications. Many intravesical therapies are expensive, and physicians must ensure they will at least recover acquisition costs. Without reliable reimbursement, even clinically valuable therapies may be difficult to provide, regardless of physician interest.

Rubenstein explains that new drugs often enter the market before receiving a dedicated J code, creating uncertainty. Although reimbursement is still possible without one, practices must invest additional effort in prior authorizations and payer communication. Insurers may be unfamiliar with newly approved treatments, which increases administrative burden and slows adoption. A permanent J code helps standardize billing and clarifies expected payment levels, often embedding reimbursement terms into payer contracts. This predictability gives practices greater confidence to prescribe newer therapies and reduces financial risk.

However, a J code does not eliminate all requirements. Patients must still meet coverage criteria, and documentation must clearly support medical necessity to ensure payment. Rubenstein emphasizes that accurate coding and recordkeeping remain essential regardless of reimbursement pathway.

Before a formal J code is established, practices typically rely on unlisted billing codes, such as general drug or biologic codes. Using these interim pathways is acceptable but requires proactive coordination with insurers, including Medicare and private payers. Physicians should confirm which codes insurers prefer, ensure they understand the therapy’s indication, and clarify reimbursement expectations in advance.

Ultimately, Rubenstein stresses that communication is the key safeguard. Problems arise not from using interim codes themselves, but from administering therapies without confirming payer awareness and approval, which can jeopardize reimbursement and limit patient access.